216 related articles for article (PubMed ID: 23435930)
21. Comparison of gadoteric acid and gadobutrol for detection as well as morphologic and dynamic characterization of lesions on breast dynamic contrast-enhanced magnetic resonance imaging.
Renz DM; Durmus T; Böttcher J; Taupitz M; Diekmann F; Huppertz A; Pfeil A; Maurer MH; Streitparth F; Bick U; Hamm B; Fallenberg EM
Invest Radiol; 2014 Jul; 49(7):474-84. PubMed ID: 24637587
[TBL] [Abstract][Full Text] [Related]
22. Gadobutrol Precedes Gd-DTPA in Abdominal Contrast-Enhanced MRA and MRI: A Prospective, Multicenter, Intraindividual Study.
Liu X; Li Z; Zhang W; Yang C; Diao Y; Duan T; Fu Y; Ren J; Bin S
Contrast Media Mol Imaging; 2019; 2019():9738464. PubMed ID: 31866800
[TBL] [Abstract][Full Text] [Related]
23. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol.
Elmholdt TR; Jørgensen B; Ramsing M; Pedersen M; Olesen AB
NDT Plus; 2010 Jun; 3(3):285-287. PubMed ID: 28657062
[TBL] [Abstract][Full Text] [Related]
24. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
[TBL] [Abstract][Full Text] [Related]
25. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body.
Hao J; Pitrou C; Bourrinet P
Invest Radiol; 2024 Feb; 59(2):124-130. PubMed ID: 37812485
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and Safety of Macrocyclic Gadobutrol in Children Aged Younger Than 2 Years Including Term Newborns in Comparison to Older Populations.
Kunze C; Mentzel HJ; Krishnamurthy R; Fleck R; Stenzel M; Bhargava R; Burrowes D; Sutter G; Schultze-Mosgau M; Santiuste M; Hahn G
Invest Radiol; 2016 Jan; 51(1):50-7. PubMed ID: 26340504
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
[TBL] [Abstract][Full Text] [Related]
28. Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan.
Tsushima Y; Awai K; Shinoda G; Miyoshi H; Chosa M; Sunaya T; Endrikat J
Jpn J Radiol; 2018 Nov; 36(11):676-685. PubMed ID: 30232584
[TBL] [Abstract][Full Text] [Related]
29. A Japanese, Multicenter, Open-label, Phase 3 Study to Investigate the Safety and Efficacy of Gadobutrol for Contrast-enhanced MR Imaging of the Central Nervous System.
Tanaka A; Masumoto T; Yamada H; Kurauchi M; Breuer J
Magn Reson Med Sci; 2016; 15(2):227-36. PubMed ID: 26687097
[TBL] [Abstract][Full Text] [Related]
30. Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients.
Splendiani A; Perri M; Marsecano C; Vellucci V; Michelini G; Barile A; Di Cesare E
Radiol Med; 2018 Feb; 123(2):125-134. PubMed ID: 28952018
[TBL] [Abstract][Full Text] [Related]
31. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol C; Hiremath S
Can Assoc Radiol J; 2018 May; 69(2):136-150. PubMed ID: 29706252
[TBL] [Abstract][Full Text] [Related]
32. A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities.
Kuwatsuru R; Takahashi S; Umeoka S; Sugihara R; Zeng M; Huan Y; Peng W; Ma L; Guo L; Teng G; Yao W; Tozaki M; Endo M; Kaji S; Ro T; Tae Hahn S; Chul Kang B; Nishimura H; Sugawara Y; Katakami N; Breuer J; Aitoku Y
J Magn Reson Imaging; 2015 Feb; 41(2):404-13. PubMed ID: 24692302
[TBL] [Abstract][Full Text] [Related]
33. Gadolinium retention within multiple rat organs after intra-articular administration of gadolinium-based contrast agents.
Ringler MD; Rhodes NG; Ayers-Ringler JR; Jakaitis DR; McDonald RJ; Kallmes DF; McDonald JS
Skeletal Radiol; 2021 Jul; 50(7):1419-1425. PubMed ID: 33404669
[TBL] [Abstract][Full Text] [Related]
34. Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system.
Gutierrez JE; Rosenberg M; Duhaney M; Simon JA; Brueggenwerth G; Agris JM; Knopp EA
J Magn Reson Imaging; 2015 Mar; 41(3):788-96. PubMed ID: 24578298
[TBL] [Abstract][Full Text] [Related]
35. P03277-A New Approach to Achieve High-Contrast Enhancement: Initial Results of an Experimental Extracellular Gadolinium-Based Magnetic Resonance Contrast Agent.
Fries P; Müller A; Seidel R; Robert P; Denda G; Menger MD; Schneider G; Buecker A
Invest Radiol; 2015 Dec; 50(12):835-42. PubMed ID: 26186281
[TBL] [Abstract][Full Text] [Related]
36. Improved display of abdominal contrast-enhanced MRA using gadobutrol: comparison with Gd-DTPA.
Liu X; Zhang W; Li Z; Fu Y; Ren J; Shen W; Wang J; Xu Y; Song B
Clin Radiol; 2019 Dec; 74(12):978.e1-978.e7. PubMed ID: 31551147
[TBL] [Abstract][Full Text] [Related]
37. Optimization of breathing instructions and timing of late arterial phase acquisition on gadobutrol-enhanced MRI of the liver.
Pinho DF; Lev-Cohain N; Awdeh H; Xi Y; Khatri G; Yokoo T; Pedrosa I
Clin Imaging; 2016; 40(6):1274-1279. PubMed ID: 27684994
[TBL] [Abstract][Full Text] [Related]
38. Gadolinium Deposition in the Brain in a Large Animal Model: Comparison of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Radbruch A; Richter H; Fingerhut S; Martin LF; Xia A; Henze N; Paulus W; Sperling M; Karst U; Jeibmann A
Invest Radiol; 2019 Sep; 54(9):531-536. PubMed ID: 31261291
[TBL] [Abstract][Full Text] [Related]
39. Effects of gadolinium-based contrast agent concentrations (0.5 M or 1.0 M) on the diagnostic performance of magnetic resonance imaging examinations: systematic review of the literature.
Lancelot E; Froehlich J; Heine O; Desché P
Acta Radiol; 2016 Nov; 57(11):1334-1343. PubMed ID: 26071496
[TBL] [Abstract][Full Text] [Related]
40. Contrast material for abdominal dynamic contrast-enhanced 3D MR angiography with parallel imaging: intraindividual equimolar comparison of a macrocyclic 1.0 M gadolinium chelate and a linear ionic 0.5 M gadolinium chelate.
Hadizadeh DR; Von Falkenhausen M; Kukuk GM; Schöneseiffen K; Gieseke J; Schild HH; Willinek WA
AJR Am J Roentgenol; 2010 Mar; 194(3):821-9. PubMed ID: 20173166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
